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Introduction: Souvenaid® containing Fortasyn® Connect is a medical food designed to support synapse synthesis
in persons with Alzheimer’s disease (AD). Fortasyn Connect includes precursors (uridine monophosphate; choline;
phospholipids; eicosapentaenoic acid; docosahexaenoic acid) and cofactors (vitamins E, C, B12, and B6; folic acid;
selenium) for the formation of neuronal membranes. Whether Souvenaid slows cognitive decline in treated persons
with mild-to-moderate AD has not been addressed.
Methods: In a 24-week, double-masked clinical trial at 48 clinical centers, 527 participants taking AD medications
[52% women, mean age 76.7 years (Standard Deviation, SD = 8.2), and mean Mini-Mental State Examination score
19.5 (SD = 3.1, range 14–24)] were randomized 1:1 to daily, 125-mL (125 kcal), oral intake of the active product
(Souvenaid) or an iso-caloric control. The primary outcome of cognition was assessed by the 11-item Alzheimer’s
Disease Assessment Scale-Cognitive Subscale (ADAS-cog). Compliance was calculated from daily diary recordings of
product intake. Statistical analyses were performed using mixed models for repeated measures.
Results: Cognitive performance as assessed by ADAS-cog showed decline over time in both control and active
study groups, with no significant difference between study groups (difference =0.37 points, Standard Error,
SE = 0.57, p = 0.513). No group differences in adverse event rates were found and no clinically relevant differences
in blood safety parameters were noted. Overall compliance was high (94.1% [active] and 94.5% [control]), which
was confirmed by significant changes in blood (nutritional) biomarkers.
Conclusions: Add-on intake of Souvenaid during 24 weeks did not slow cognitive decline in persons treated for
mild-to-moderate AD. Souvenaid was well tolerated in combination with standard care AD medications.
Trial registration: Dutch Trial Register number: NTR1683.Introduction
By 2050 the number of individuals living with dementia
due to Alzheimer’s disease (AD) worldwide is estimated
to increase from 36 million to 115 million people [1],
with two-thirds of persons affected living in developing
countries. Given the worldwide public health impact of
AD, increased efforts are needed to develop novel and
effective AD interventions that are easy to deploy and are
not resource intensive. AD is a neurodegenerative condition* Correspondence: Raj_C_Shah@rush.edu
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reproduction in any medium, provided the orassociated with cognitive and functional ability loss. While
the pathogenesis of AD involves the extraneuronal depos-
ition of the amyloid-beta peptide and phosphorylation of
intraneuronal tau proteins [2], loss of synapses is thought
to play an important downstream role in the process of
cognitive loss [3,4]. The investigational nutrition product,
Souvenaid (Nutricia N.V., Zoetermeer, the Netherlands), is
a liquid medical food formulation containing the specific
nutrient combination, Fortasyn Connect (Nutricia N.V.).
Fortasyn Connect includes nutritional precursors and
cofactors for the synthesis of neuronal membranes and is
designed to support synapse formation and function in
patients with AD [5]. Phosphatide molecules plus synapticd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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can be increased by co-administration of rate-limiting
precursors via the Kennedy pathway [6,7].
In a multicenter, European, randomized, double-blind,
controlled proof-of-concept trial (Souvenir I), 225 drug-
naïve patients with mild AD were randomized to once-
daily intake of Souvenaid or control [8]. In this trial, delayed
verbal recall score of the Wechsler Memory Scale – revised
was significantly improved after 12 weeks of intervention
with Souvenaid as compared with control product.
The 13-item modified Alzheimer’s Disease Assessment
Scale – Cognitive Subscale (ADAS-cog) score, the other
co-primary outcome, was no different in the Souvenaid
group compared with the control group, but secondary
analyses pointed to a potential benefit in individuals with
worse baseline performance on the ADAS-cog [9]. Based
on these results, two double-blind, randomized controlled
clinical trials were designed. The Souvenir II study exam-
ined the effect of longer treatment duration (24 weeks) with
Souvenaid as compared with control product on memory
performance in drug-naïve mild AD [10]. Since the ADAS-
cog may be more sensitive to change in moderate AD [11]
and since Souvenaid had not been tested in moderate AD
patients already taking AD medications, the S-Connect
study was designed. In this 24-week, double-masked, paral-
lel, randomized, controlled clinical study, the efficacy and
tolerability of Souvenaid was investigated in 527 persons
with mild-to-moderate AD taking stable doses of US Food
and Drug Administration-approved symptomatic AD treat-
ments (that is, cholinesterase inhibitors and/or memantine),
using the ADAS-cog as the primary outcome measure. The
results of the S-Connect study are presented here.
Methods
Standard protocol approvals, registrations, and
patient consents
The S-Connect study was approved by the Institutional
Review Boards of each of the 48 clinical sites based in
the United States. The study was conducted in accord-
ance with the Declaration of Helsinki, the International
Conference on Harmonisation guidelines for Good Clinical
Practice as appropriate for nutritional products, and local
legislation of the country in which the research was con-
ducted. The trial was registered with The Dutch National
Trial Register (NTR1683). Written informed consent was
obtained from all study participants and study partners
prior to conducting study procedures.
Patients
Community and clinic-based recruitment efforts including
mass-media presentations in certain markets that received
Institutional Review Board approval were utilized to iden-
tify potential participants. Persons expressing interest in the
study were invited for a screening evaluation. Screeninginvolved confirmation of eligibility criteria via the collection
of demographic information, medical history and con-
comitant medications, and the administration of the
Mini-Mental State Examination (MMSE) [12]. Inclusion
criteria were: age 50 years or older; diagnosis of probable
AD according to the joint working group of the National
Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related
Disorders Association [13]; a MMSE score between 14 and
24 inclusive; use of US Food and Drug Administration-
approved AD medication on a stable dose for at least
4 months prior to baseline; and availability of a responsible
study partner. Exclusion criteria were: diagnosis of a
neurological/psychiatric disease significantly contributing
to cognitive difficulties other than AD; a 15-item Geriatric
Depression Scale [14] score >4; recent use of potent
anticholinergic agents, antipsychotics, omega-3 fatty acid-
containing supplements and/or oily fish consumption more
than twice a week, high-energy or high-protein nutritional
supplements or medical foods, vitamins B, C and/or E
containing supplements at >100% of daily value, or other
investigational products; recent change in lipid-lowering
medications, antidepressants, or antihypertensives; alcohol
or drug abuse in the opinion of the investigator; or
institutionalization in a nursing home. Participants who
discontinued the study prematurely were not replaced.
Study group allocation
Participants meeting eligibility criteria at baseline were
randomized in a 1:1 fashion to active product (Souvenaid
containing Fortasyn Connect) or an iso-caloric control
product that lacked Fortasyn Connect but was similar
in appearance and taste with the active product (see
Additional file 1 for detailed product composition). Both
study products were available in two flavors (strawberry
or vanilla) as a 125 ml (125 kcal) drink in a tetra package
and were to be taken once daily for 24 weeks. Participants
chose one of the two flavors based on personal taste
preferences. Allocation to active or control product was
performed through a central randomization procedure
in the Electronic Data Capture system using four different
randomization codes (A, B, C, and D). Participants,
study partners, and study staff were masked to study
group assignment during the trial. Unmasking did not
occur until initial statistical modeling of the primary
outcome was complete.
Procedures
Participants underwent a baseline visit that included
functional evaluation and global clinician rating. The
main efficacy outcome and secondary outcomes were
measured at baseline, 12 and 24 weeks, except for the
blood parameters that were assessed at baseline and
24 weeks. Additional brief evaluations occurred at weeks 6
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staff were conducted at 3, 9, 15, and 21 weeks as well as
2 weeks after completion. Adverse events and the use of
concomitant medication, including AD medication, were
recorded at every in-person and telephone evaluation. All
participants who withdrew early had study termination
visits equivalent to week 24.
Primary outcome
The primary outcome measure was the effect on cognition
of the active product as measured by the 11-item ADAS-cog
[15]. The ADAS-cog assesses memory, language, praxis,
attention, and other cognitive abilities. The total ADAS-
cog score ranges from 0 (no cognitive deficit) to 70 (severe
cognitive deficit), calculated as the numbers of errors a
participant made. All examiners were trained centrally
before conducting the tests for the primary and secondary
outcome assessments. While no formal continuing training
program during the study was implemented, additional
training was provided as needed if cognitive data collection
issues were noted by centrally trained study monitors.
No screening or practice sessions for cognitive outcomes
were conducted prior to baseline.
Secondary outcomes
The secondary outcomes assessed the effect on cognition,
functional abilities, global clinical impression, safety,
and nutritional blood parameters of the active product
as compared with control.
To assess cognition in a complementary manner to the
ADAS-cog, a cognitive test battery composed of the Digit
Span from the Wechsler Memory Scale – Third Edition
[16], the Concept Shifting Test [17], the Letter Digit Sub-
stitution Test [18], and Category Fluency [19] was admin-
istered to measure attention and concentration, executive
function, processing speed, and semantic memory, respect-
ively. The total score on the Digit Span tests was calculated
as the total number of Digits Forward and Digits Backward
sequences correctly repeated (ranging from 0 to 24). The
Concept Shifting Test score was calculated from the time
needed to complete each of the subtests, resulting in a con-
cept shifting score. The Letter Digit Substitution Test score
was the total number of correctly substituted numbers in
60 seconds. The Category Fluency score was the total num-
ber of different animals named in 60 seconds. Using the
mean and standard deviation (SD) from the baseline evalu-
ation of all participants, raw scores were converted to z
scores. For the Concept Shifting Test score, the z scores
were multiplied by −1, so that positive z scores correspond
to better performance. The z scores of the four neuro-
psychological tests were then averaged to construct a global
cognitive function composite score.
The 23-item Alzheimer’s Disease Cooperative Study –
Activities of Daily Living scale, completed by a studypartner, measured the ability of the participant to perform
baseline and instrumental activities during the prior month
[20]. Total scores ranged from 0 (nonperformance or need
for extensive help) to 78 (independent performance). The
Clinical Dementia Rating – Sum of Boxes gave a global clin-
ical impression of the participant and total scores ranged
from 0 (no impairment) to 18 (severe impairment) [21,22].
Safety assessments included the examination of patient
medical history, the recording of (serious) adverse events,
concomitant medication and nutritional supplement use,
and the monitoring of vital signs and safety laboratories for
liver function, renal function, and coagulation (at selected
sites only). An Independent Data Monitoring Committee
and the study medical monitor reviewed adverse events.
Serious adverse events were reviewed by the Institutional
Review Board of each site. Product intake as recorded
in a study partner-supervised patient-reported diary on
a daily basis was used to measure product compliance.
Study product compliance was calculated as the percentage
of product used throughout the study period as compared
with the prescribed dosage.
Nutritional blood parameters were docosahexaenoic
acid and eicosapentaenoic acid fractions in erythrocyte
membranes along with plasma vitamin E and homocyst-
eine levels. Venous blood samples were taken, with a
maximum of 30 ml in total per participant for each of
the baseline and end-of-study visits, were processed and
were stored in a −80°C freezer until batch shipped on
dry ice. After extracting lipids from erythrocyte mem-
branes, the fatty acid profile in erythrocyte membranes
was assayed by gas chromatography. Plasma vitamin E
levels were measured using high-performance liquid
chromatography to determine the content of alpha-
tocopherol. Homocysteine levels were measured using
high-performance liquid chromatography with fluores-
cence detection after preparing a derivate.
Sample size
Sample size calculation was based on the repeated meas-
urement design with an estimated difference between
the groups of 0 points at baseline, of 0.95 points after
12 weeks of intervention, and of 1.9 points after 24 weeks
of intervention with a SD of difference of 10 and an
average within-subject correlation of 0.80 over time.
Using a type I error of 0.05, a power of 80% and assum-
ing a 15% drop-out rate, this resulted in a sample size
of 500 randomized patients. A pre-specified, blinded,
re-estimation of the nuisance parameters was conducted
for 474 participants to assess whether the calculated
sample size was adequate. Based on review of these data
along with safety information by the Independent Data
Monitoring Committee and the Steering Committee,
the study was continued without change using the ori-
ginally calculated sample size.
Figure 1 Flow of participants in the trial. AST, all subjects treated;
ITT, intent to treat.
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Efficacy analyses were performed for the intent-to-treat
cohort, including all randomized subjects. Safety ana-
lyses were performed for the all-subjects-treated sample
(that is, all randomized subjects who received at least
one unit of the study product).
Efficacy analyses utilized mixed models for repeated
measures. Time was included in the model as a continu-
ous variable using a 24-week period as the unit and with
the value 0 at baseline. The model included random in-
tercepts and random slopes for time. The fixed effects of
the model consisted of the treatment group, the linear
effect of time, and the interaction of treatment group
and time. An effect of the treatment group is indicated
by statistical significance of the treatment by time inter-
action. The model takes baseline measurements into ac-
count by including them in the outcome vector. Models
were then repeated with adjustments for pre-specified
confounders (that is, age, gender, education level, type of
AD medication, baseline MMSE score, and presence of an
apolipoprotein ε4 allele). If model assumptions of normal-
ity, independence, and constant variance of errors were not
adequately met, nonparametric alternatives were used. All
statistical analyses were performed using SAS 9.2 (SAS
Institute Inc,. Cary, North Carolina, USA). All statistical
tests were two-tailed at the 0.05 level of significance.
Results
Participant flow
The trial was conducted between 26 March 2009 and 3
March 2011, including 18 months of recruitment. Of
the 703 participants who consented, 167 were excluded
because they did not meet the inclusion criteria and
nine withdrew from the study prior to randomization
(Figure 1). The resulting 527 participants were randomized
to Souvenaid (active product, n = 265) or control product
(n = 262). Compared with the intent-to-treat sample,
three subjects were excluded from the all-subjects-treated
population because they had not taken any study product.
Of the 527 subjects who were randomized, 76 (14.4%)
withdrew from the study early (n = 37 (14.0%) subjects
from the active study group; n = 39 (14.9%) subjects
from the control group).
Baseline characteristics are summarized in Table 1.
Randomized participants had a mean age of 76.7 years
(SD = 8.2), and a mean education level (defined as number
of years after finishing primary school) of 6.5 years
(SD = 3.5). Women comprised 52% of the cohort and 94%
of participants were White (including Hispanics). The
mean time from initial AD diagnosis was 33.8 months
(SD = 27.4). The mean duration of AD medication use
was 30.1 months (SD = 25.9); 34% of participants were
taking an acetylcholinesterase inhibitor agent only, 6% were
taking memantine only, and 60% were on both treatments.The mean baseline ADAS-cog score was 23.6 (SD = 9.5)
and the mean baseline MMSE was 19.5 (SD = 3.1). Baseline
participant characteristics of the cohort did not differ sig-
nificantly by study group (Table 1).
Primary outcome measure
ADAS-cog data are presented in Table 2 and Figure 2.
ADAS-cog scores showed an increase over time in
both study groups, indicating cognitive decline, without sig-
nificant differences between the active and control group
over 24 weeks (between-group difference of 0.37 points,
standard error = 0.57, P = 0.513, mixed models for repeated
measures). The conclusions were unchanged in a subse-
quent model that corrected for pre-specified confounders.
Secondary outcome measures
No differences between study groups were observed over
24 weeks in performance on the cognitive test battery,
the Alzheimer’s Disease Cooperative Study – Activities
of Daily Living, and the Clinical Dementia Rating – Sum of
Boxes (Table 2). Mean compliance was 94.1% (SD = 11.9)
for the active group and 94.5% (SD = 13.2) for the control
group (P = 0.689 for between-group difference, t test). A
significant uptake of docosahexaenoic acid (Figure 3a) and
eicosapentaenoic acid into the erythrocyte membranes, in-
creased plasma vitamin E levels (Figure 3b) and decreased
homocysteine levels were observed for the active group
compared with the control group over the 24-week inter-
vention period (P <0.001, Mann–Whitney U test).
Safety and tolerability
The 24-week study completion rate was 86% (n = 228) in
the group receiving active product and 85% (n = 223) in
Table 1 Baseline participant characteristics by study group
Characteristic Active product Control product
(n = 265) (n = 262)
Demographics
Age (years) 76.6 (8.2) 76.9 (8.2)
Female 139 (52%) 135 (52%)
Education after finishing primary school 6.7 (3.6) 6.4 (3.5)
White (including Hispanic) 250 (94%) 247 (94%)
Mean time from initial AD diagnosis (months) 32.7 (25.0) 34.9 (29.6)
Duration of AD medication use (months) 28.8 (22.9) 31.5 (28.7)
Type of AD medication used
Acetylcholinesterase inhibitor 87 (32.8%) 92 (35.1%)
Memantine 13 (4.9%) 19 (7.3%)
Acetylcholinesterase inhibitor and memantine combined 164 (61.9%) 151 (57.6%)
Body mass index (kg/m2) 26.2 (4.5) 26.6 (4.6)
Mini-Mental State Examination score (out of 30) 19.5 (3.2) 19.4 (3.0)
Presence of apolipoprotein E ε4 allele
No 87 (39.2%) 84 (42.0%)
Yes 135 (60.8%) 116 (58.0%)
Unknown 43 62
Data presented as mean (standard deviation) or number (%). AD, Alzheimer’s disease.
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were reported in 150 participants, compared with the re-
port of 445 adverse events in 165 participants in the control
group (P = 0.130, Fisher’s exact test, comparing percentage
of subjects with at least one adverse event). The numberTable 2 Descriptive statistics for ADAS-cog, cognitive test bat
Active product
ADAS-cog
Baseline 23.89 ± 9.59 (258)
Week 24 25.44 ± 11.56 (220)
Δ week 24 – baseline 1.88 ± 6.44 (218)
Cognitive Test Battery, z score
Baseline 0.08 ± 0.75 (228)
Week 24 0.09 ± 0.74 (182)
Δ week 24 – baseline −0.10 ± 0.47 (179)
ADCS-ADL total score
Baseline 57.95 ± 13.36 (265)
Week 24 54.66 ± 15.56 (228)
Δ week 24 – baseline −3.74 ± 9.76 (228)
CDR-SB
Baseline 6.18 ± 3.01 (264)
Week 24 6.89 ± 3.35 (227)
Δ week 24 – baseline 0.77 ± 1.96 (226)
Data presented as mean ± standard deviation (n). ADAS-cog, Alzheimer’s Disease As
Cooperative Study Activity of Daily Living; CDR-SB, Clinical Dementia Rating scale –
product, except for values in parentheses that are P values from mixed model for reand proportion of patients experiencing one or more
adverse events are summarized by body system in Table 3.
No significant or relevant differences in adverse events by
body system were found. In the active group 34 serious
adverse events in 27 subjects were reported, comparedtery, ADCS-ADL and CDR-SB (intent-to-treat cohort)
Control product P valuea
23.39 ± 9.34 (257) 0.550
24.42 ± 10.95 (208) 0.349
1.52 ± 5.63 (207) 0.547 (0.513)
−0.02 ± 0.71 (235) 0.153
0.01 ± 0.71 (182) 0.260
−0.05 ± 0.40 (178) 0.301 (0.323)
57.38 ± 13.37 (262) 0.623
54.15 ± 15.91 (223) 0.731
−3.66 ± 8.03 (223) 0.926 (0.767)
6.45 ± 2.89 (259) 0.296
7.01 ± 3.41 (223) 0.709
0.69 ± 1.90 (222) 0.676 (0.500)
sessment Scale – Cognitive Subscale, ADCS-ADL, Alzheimer’s Disease
Sum of Boxes; Δ, difference. aP values from t tests, active product versus control
peated measures.
Figure 2 Mean change from baseline in the Alzheimer’s Disease Assessment Scale – Cognitive Subscale score. Effects of 24-week intake
of study product on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog) in the intent-to-treat cohort. Error bars represent
standard errors. P = 0.513 (mixed models for repeated measures).
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control group. None of the serious adverse events were
considered to be related to the use of the study prod-
uct, except for one serious adverse event (confusion)
that was considered to possibly be related to the use of
the study product (control). Six serious adverse events
resulted in premature discontinuation of the study, in-
cluding two serious adverse events in the active group
(fall and intracranial hemorrhage) and four serious adverse
events in the control group (fall, myocardial infarction,
nonsmall-cell metastatic lung cancer and malignant
mesothelioma), of which malignant mesothelioma resulted
in death of the patient. No clinically relevant differences
between study groups in vital signs and in blood param-
eters were noted.
Discussion
In this clinical trial of persons with mild-to-moderate
AD on stable treatment with available AD medications,
the addition of daily oral intake of Souvenaid did not re-
sult in 24-week changes in cognitive function, functional
abilities, or global clinical impression. Souvenaid was safe
and well tolerated and compliance was high, which was
confirmed by significantly marked changes in nutritional
blood parameters.
Secondary analysis of the proof-of-concept study with
Souvenaid [9] pointed to a potential benefit on ADAS-cog
in patients with higher ADAS-cog scores (more impaired
cognition) at baseline. However, the current, adequately
powered clinical trial did not demonstrate an effect oncognition in patients with mild-to-moderate AD receiving
AD medication. In the S-Connect study, both the treatment
and control groups showed a moderate increase of ADAS-
cog scores, suggesting cognitive deterioration, which was
consistent with expectations in a population of mild-to-
moderate AD patients [23]. Why the active product did
not result in slowing cognitive decline in the current study
population of persons treated for mild-to-moderate AD is
not certain. One potential reason is that a nutrition inter-
vention targeting synaptogenesis may favor earlier use in
(very) mild dementia due to AD [8,10] or in pre-dementia
stages of AD. In the past decade, clinical trials with nutri-
tional interventions as well as AD drugs and biologics
have failed to show benefits in slowing cognitive decline in
mild-to-moderate AD. A leading hypothesis for these out-
comes has been that the patients in the studies were too
far down the pathologic cascade when the neuronal dam-
age and synaptic dysfunction accumulated to an irrevers-
ible degree. The hypothesis for the mechanism of action
for the current active product is based on its effect on syn-
aptogenesis [24]. Synaptic dysfunction and synapse loss
are key hallmarks of AD [25,26], which are present in the
very early stage of the disease, even before the emergence
of clinical symptoms [27], and strongly correlate with
cognitive deterioration [28]. The production of synap-
ses requires neurons, so the potential to benefit from
synaptogenesis may be limited in a more moderate stage
of dementia due to AD as compared with (very) mild
dementia due to AD because of the higher levels of neu-
rodegeneration. In more moderate stages of the clinical
Figure 3 Mean docosahexaenoic acid and plasma vitamin E
levels. Effects of 24-week intake of study product on (a) the
percentage docosahexaenoic acid (DHA) of total fatty acids in
erythrocyte membrane and (b) plasma vitamin E levels (μmol/l) in
the intent-to-treat cohort. Error bars represent standard errors.
P <0.001 (Mann–Whitney U test).
Table 3 Participants experiencing one or more adverse






Total participants 264 260
Body as a whole 24 (9.1) 33 (12.7) 0.208
Back pain, leg pain, syncope
Central and peripheral nervous
system disorders
27 (10.2) 21 (8.1) 0.450
Headache, dizziness
Gastrointestinal system disorders 41 (15.5) 38 (14.6) 0.808
Diarrhea, vomiting, nausea
Metabolic and nutritional disorders 19 (7.2) 19 (7.3) >0.99
Vitamin D deficiency,
hypercholesterolemia, hypokalemia
Musculoskeletal system disorders 24 (9.1) 15 (5.8) 0.183
Arthralgia, fracture
Psychiatric disorders 32 (12.1) 43 (16.5) 0.170
Anxiety, agitation, depression,
confusion
Respiratory system disorders 50 (18.9) 42 (16.2) 0.423
Pharyngitis, upper respiratory
tract infection
Skin and appendage disorders 8 (3.0) 18 (6.9) 0.045
Pruritus, increased sweating
Urinary system disorders 25 (9.5) 19 (7.3) 0.432
Urinary tract infection, urinary
incontinence
Other 20 (7.6) 27 (10.4) 0.287
Fall, surgical intervention
Data presented as number (%). aFor body systems where >5% of participants
in either study group reported an event. If a participant experienced the same
event more than once within the same body system, the participant was only
counted once for the statistical analysis. Adverse events occurring in <5% of
patients were: application site disorders, endocrine disorders, hearing and
vestibular disorders, heart rate and rhythm disorders, liver and biliary system
disorders, myocardial/endocardial/pericardial and valve disorders, neoplasm,
platelet, bleeding and clotting disorders, red blood cell disorders, reproductive
disorders (male), resistant mechanism disorders, special senses disorders,
vascular (extracardiac) disorders, vision disorders, white cell and
reticuloendothelial disorders. bFisher’s exact test.
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dysfunction present may overwhelm potential benefits
of Souvenaid on synaptic membrane formation. Current
intervention strategies targeting amyloid-beta also are being
redirected from mild to moderate AD to asymptomatic or
early symptomatic stages of AD [29]. Similarly, the use of
Souvenaid may be more beneficial in patients who start
nutritional intervention in an earlier stage of the AD disease
process, when the neurodegenerative damage is still limited,
and thus with greater possibilities to delay cognitive decline.
An alternate reason for the study findings is that Souvenaid
may not convey a benefit on top of the use of currently
available symptomatic pharmacologic therapies in the
more moderate stages of the disease. Proving this
hypothesis requires further investigation of Souvenaid
in drug-naïve patients with moderate AD.The main strength of the present study is that it pro-
vides an informative null regarding add-on therapy
with Souvenaid in slowing cognitive decline in a more
advanced stage of dementia due to AD. The study was
powered adequately to detect a difference between treat-
ment groups on cognitive function. Compliance with active
product was high; there were no significant or relevant
differences in the adverse event profile and proportion
of subjects discontinuing the study due to adverse events
between the active product and control groups; the overall
drop-out rate (14.4%) was slightly lower than anticipated
a priori; and the active product resulted in the predicted
change in peripheral nutritional blood biomarkers. Also,
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measures as conducted in pharmaceutical drug trials for
regulatory approval was utilized. A limitation of this clinical
research study was the inability to determine whether
the null result clearly was due to the active product not
being effective in the moderate stages of dementia due
to AD or was due to not having an additional effect on
top of currently approved pharmacological therapies.
Also, there was no continuing training program on the
cognitive batteries in order to minimize the risk of testing
drift during the course of the clinical trial.
This study is part of the Souvenaid clinical trial program
that started in 2006 and was based on years of preclinical
research examining how specific nutrients may support
synaptic function [5]. The multidecade effort to understand
the role of nutrients involved in the Kennedy pathway con-
tinues to provide insights to help researchers and clinicians
better understand the nuanced application of Souvenaid in
AD. The null results from the current study in combination
with the two other completed clinical trials that showed
an effect on memory performance in drug-naïve persons
in mild stages of AD [8,10] have led to the focus on use of
Souvenaid for cognitive function in the very early stages of
the disease. Other randomized controlled trials to obtain
more information on the mode of action and long-term
efficacy of Souvenaid currently are ongoing, including
the 24-month European Union-funded LipiDiDiet study
(Dutch Trial Register #NTR1705) in prodromal AD.
Conclusion
This S-Connect clinical trial establishes the fact that
Souvenaid as an add-on intervention does not slow overall
cognitive decline and is safe and well tolerated in persons
with mild-to-moderate AD using AD medication.
Additional file
Additional file 1: Table S1. Presenting the nutritional composition of
Souvenaid and control product.
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